Technology

A proprietary oral delivery platform for therapeutic proteins

Oral Peptide Delivery Challenge

Currently, most protein therapies are administered via frequent intravenous, subcutaneous or intramuscular injections. In chronic diseases where patients require persistent management, these cumbersome, often painful and high-priced injections can create a major treatment gap.

From a technical standpoint, oral delivery of therapeutic proteins is challenging due to the enzymatic degradation within the gastrointestinal tract and poor absorption into the blood stream due to the proteins’ polarity and molecular weight. 

Platform

N-Tab™- Entera's Proprietary Oral Delivery Platform

Entera’s Proprietary Technology N-Tab™ – Synergistically Protects & Transports Large Molecules

  1. Prevents the degradation of the therapeutic protein in the GI tract; maintains the integrity of the protein (stability)
  2. Enhances peptide absorption by increasing transcellular transport (bioavailability)